To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a recent conference in Miami, speakers showed data on potential fluid biomarkers and PET tracers that could differentiate the two main proteinopathies, tau and TDP-43. They also discussed nascent markers and debuted an AI algorithm that improves the diagnostic capabilities of FDG-PET scans.